Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? [Yahoo! Finance]
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application